8-K: Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split and Authorized Share Reduction

Sensei Biotherapeutics, Inc. has filed an amendment to its Certificate of Incorporation to effect a one-for-twenty reverse stock split and reduce its authorized common shares from 250 million to 12.5 million, effective June 16, 2025.

Summary

• Sensei Biotherapeutics, Inc. (the "Company") filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation on June 12, 2025.
• The amendment effects a one-for-twenty (1-for-20) reverse stock split of its outstanding common stock.
• The total number of authorized shares of common stock will be reduced from 250,000,000 to 12,500,000.
• The amendment will be effective at 5:00 p.m. Eastern Time on June 16, 2025.
• The reverse stock split and corresponding shares reduction were approved by stockholders on May 21, 2025, and by the board of directors on June 3, 2025.
• Every twenty (20) shares of issued and outstanding common stock will automatically combine into one (1) share, without change in par value per share.
• Proportionate adjustments will be made to the per share exercise price and number of shares for stock options, restricted stock unit awards, and warrants.
• No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment based on the average closing sales prices over the five trading days preceding the filing date.
• The reverse stock split will affect all stockholders proportionately and will not affect percentage ownership, except for fractional shares.
• The Company's common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis when the market opens on June 17, 2025.
• The new CUSIP number for the common stock following the reverse stock split is 81728A207.

Sentiment

Score: 3

Explanation: The sentiment is generally negative as a reverse stock split often signals underlying stock price weakness and is typically a defensive measure to maintain exchange listing, rather than a sign of strong financial performance or growth.

Negatives

• The necessity of a reverse stock split often indicates a sustained low stock price, which can be perceived negatively by investors and may reflect underlying challenges for the company.

Future Outlook

The document primarily details a corporate action (reverse stock split and authorized share reduction) and does not provide broader forward-looking statements or guidance regarding the company's operational or financial performance beyond the effective date of the split.

Management Comments

• The specific one-for-twenty (1-for-20) Reverse Stock Split and corresponding Shares Reduction was subsequently approved by the Company's board of directors on June 3, 2025.

Industry Context

Reverse stock splits are a common corporate action across various industries, including biotechnology, often undertaken by companies to increase their per-share stock price to meet minimum bid price requirements of stock exchanges like Nasdaq, thereby avoiding potential delisting. This action by Sensei Biotherapeutics aligns with such practices observed in the broader market for companies facing similar stock price challenges.

Corporate Governance

Stakeholder Impact

• Shareholders: Will own fewer shares but maintain the same percentage ownership (except for minor adjustments due to fractional shares, which will be cashed out). The per-share price is expected to increase proportionately.
• Stock Option Holders/RSU Holders/Warrant Holders: The number of shares issuable upon exercise/vesting and the exercise prices will be proportionately adjusted to reflect the split, maintaining the intrinsic value of their holdings.

Next Steps

• The Company's common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis when the market opens on June 17, 2025.

Key Dates

Keywords

Reverse Stock Split, Authorized Shares Reduction, Sensei Biotherapeutics, SNSE, Nasdaq Capital Market, SEC Filing, Corporate Action, Common Stock, Biotechnology, Corporate Governance